JP2021511387A5 - - Google Patents

Info

Publication number
JP2021511387A5
JP2021511387A5 JP2020561600A JP2020561600A JP2021511387A5 JP 2021511387 A5 JP2021511387 A5 JP 2021511387A5 JP 2020561600 A JP2020561600 A JP 2020561600A JP 2020561600 A JP2020561600 A JP 2020561600A JP 2021511387 A5 JP2021511387 A5 JP 2021511387A5
Authority
JP
Japan
Prior art keywords
seq
monoclonal antibody
antigen
binding fragment
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020561600A
Other languages
English (en)
Japanese (ja)
Other versions
JP7458993B2 (ja
JP2021511387A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/015025 external-priority patent/WO2019147863A2/en
Publication of JP2021511387A publication Critical patent/JP2021511387A/ja
Publication of JP2021511387A5 publication Critical patent/JP2021511387A5/ja
Priority to JP2023221150A priority Critical patent/JP2024038169A/ja
Application granted granted Critical
Publication of JP7458993B2 publication Critical patent/JP7458993B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020561600A 2018-01-25 2019-01-24 Ｍｉｃａ／ｂ抗体および使用方法 Active JP7458993B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023221150A JP2024038169A (ja) 2018-01-25 2023-12-27 Ｍｉｃａ／ｂ抗体および使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862621892P 2018-01-25 2018-01-25
US62/621,892 2018-01-25
PCT/US2019/015025 WO2019147863A2 (en) 2018-01-25 2019-01-24 Mica/b antibodies and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023221150A Division JP2024038169A (ja) 2018-01-25 2023-12-27 Ｍｉｃａ／ｂ抗体および使用方法

Publications (3)

Publication Number Publication Date
JP2021511387A JP2021511387A (ja) 2021-05-06
JP2021511387A5 true JP2021511387A5 (https=) 2022-02-01
JP7458993B2 JP7458993B2 (ja) 2024-04-01

Family

ID=67396240

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020561600A Active JP7458993B2 (ja) 2018-01-25 2019-01-24 Ｍｉｃａ／ｂ抗体および使用方法
JP2023221150A Pending JP2024038169A (ja) 2018-01-25 2023-12-27 Ｍｉｃａ／ｂ抗体および使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023221150A Pending JP2024038169A (ja) 2018-01-25 2023-12-27 Ｍｉｃａ／ｂ抗体および使用方法

Country Status (10)

Country Link
US (2) US20210047417A1 (https=)
EP (1) EP3743109A4 (https=)
JP (2) JP7458993B2 (https=)
KR (1) KR102731953B1 (https=)
CN (1) CN112566659A (https=)
AU (1) AU2019211411B2 (https=)
BR (1) BR112020015142A2 (https=)
IL (1) IL276187B1 (https=)
MX (1) MX2020007880A (https=)
WO (1) WO2019147863A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3768715A1 (en) 2018-03-23 2021-01-27 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
MX2021001254A (es) 2018-07-31 2021-05-12 Cullinan Mica Corp Anticuerpos anti-mica/b que bloquean la liberación de mica/b y métodos de uso.
WO2020035345A1 (en) 2018-08-14 2020-02-20 Innate Pharma Treatment of colorectal cancer by a combination of an anti-mica antibody and an anti-nkg2a antibody
CA3186062A1 (en) * 2020-08-10 2022-02-17 Marion BENEZECH Cell surface mica and micb detection using antibodies
CN114369161B (zh) * 2021-12-28 2023-06-23 合肥天港免疫药物有限公司 Mica抗体及其应用
CN114369162B (zh) * 2021-12-28 2023-05-30 合肥天港免疫药物有限公司 抗体及其应用
JP2025512137A (ja) * 2022-04-08 2025-04-16 ディーツーエム バイオセラピューティクス リミテッド 抗ｍｉｃａ／ｂ抗体及びその使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1857116A1 (en) * 2006-05-19 2007-11-21 Novoplant GmbH Antigen binding polypeptides against spike glycoprotein (S2) of bovine coronavirus
BRPI0808551B1 (pt) * 2007-03-01 2022-04-05 Symphogen A/S Composições de anticorpo para o receptor do fator de crescimento antiepidérmico recombinante, molécula de ligação bi-específica e composição farmacêutica que os compreende
US8753640B2 (en) * 2011-05-31 2014-06-17 University Of Washington Through Its Center For Commercialization MIC-binding antibodies and methods of use thereof
HUE034044T2 (en) * 2011-09-30 2018-01-29 Dana Farber Cancer Inst Inc Therapeutic peptides
EP2970490A4 (en) * 2013-03-15 2017-04-26 Novelogics Biotechnology, Inc. Antibodies to mica and micb proteins
WO2015003114A1 (en) * 2013-07-05 2015-01-08 University Of Washington Through Its Center For Commercialization Soluble mic neutralizing monoclonal antibody for treating cancer
KR102206029B1 (ko) * 2014-01-27 2021-01-20 삼성전자주식회사 Ang-2에 특이적으로 결합하는 항체 및 그의 용도
KR102763121B1 (ko) * 2015-02-06 2025-02-04 내셔널 유니버시티 오브 싱가포르 치료적 면역 세포의 효능의 향상 방법
US11780924B2 (en) * 2016-06-21 2023-10-10 University Of Oslo HLA binding vaccine moieties and uses thereof

Similar Documents

Publication Publication Date Title
JP2021511387A5 (https=)
JP2025111463A5 (https=)
JP2023509448A5 (https=)
JP2019536470A5 (https=)
JP2018512379A5 (https=)
JP2017536354A5 (https=)
JP2019513018A5 (https=)
IL280487B2 (en) Anti-mica/b antibodies that block mica/b shedding and methods of use
JP2017535257A5 (https=)
JP2019527194A5 (https=)
JP2022533538A5 (https=)
CN110799543A (zh) 肝细胞癌的免疫治疗
RU2019121086A (ru) Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1)
RU2016137110A (ru) Антитела к компоненту комплемента с5
JP2014529610A5 (https=)
JP2024520188A5 (https=)
JP2024532489A5 (https=)
JP2023549537A5 (https=)
JP2022549172A5 (https=)
JP2020513759A5 (https=)
JP2023506465A5 (https=)
RU2019121106A (ru) Иммунотерапия с применением антител, связывающих белок 1 программируемой смерти клеток (pd-1)
JP2021525806A5 (https=)
JP2022500455A5 (https=)
JP2022517216A5 (https=)